Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Fredric N. Eshelman currently holds 9,211,769 shares of Valeant Pharmaceuticals International, Inc. (VRX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Fredric N. Eshelman has been a net buyer of VRX stock. They have purchased $84.6M and sold $64.8M worth of shares.
Fredric N. Eshelman's most recent insider trade was on Apr 1, 2022, when they sold 4,545,455 shares at $0.00 per share.
Fredric N. Eshelman serves as Executive at Valeant Pharmaceuticals International, Inc. (VRX). They have executed 975 insider transactions totaling $149.4M over their tenure at the company.
Fredric N. Eshelman holds the position of Executive at Valeant Pharmaceuticals International, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 20 years and currently hold a stake valued at $0.
Fredric N. Eshelman has shown a buying trading pattern, with $84.6M in total purchases and $64.8M in total sales across all transactions. Their most recent activity indicates a tendency to accumulate shares.
The largest transaction by Fredric N. Eshelman was on Feb 12, 2021, when they purchased $21.0M worth of ARAV shares. This transaction involved 2,875,000 shares at $7.29 per share.
Fredric N. Eshelman currently owns 9,211,769 shares of Valeant Pharmaceuticals International, Inc. (VRX), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Fredric N. Eshelman's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Fredric N. Eshelman has 975 Form 4 filings on record as an insider at Valeant Pharmaceuticals International, Inc..
Set alerts for Fredric N. Eshelman and 40,000+ other insiders.